# A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus

> **NCT02437890** · PHASE2 · COMPLETED · sponsor: **Ablynx, a Sanofi company** · enrollment: 312 (actual)

## Conditions studied

- Lupus Erythematosus, Systemic

## Interventions

- **BIOLOGICAL:** ALX-0061
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02437890
- **Lead sponsor:** Ablynx, a Sanofi company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2018-01
- **Final completion:** 2018-01
- **Target enrollment:** 312 (ACTUAL)
- **Last updated:** 2019-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02437890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02437890, "A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02437890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*